Pharmacology Quiz: Absorption And Bioavailability
18 questions · exam conditions
0:00
Absorption And BioavailabilityQuestion 1 of 18

A weakly acidic drug with a pKa of 4.0 is administered orally. Considering only the chemical environment, in which location will the drug exist predominantly in its non-ionized, lipophilic form that favors passive membrane diffusion: stomach (pH 2.0) or upper small intestine (pH 6.0)?

Stomach, because pH < pKa favors the non-ionized form of weak acids.
Small intestine, because pH > pKa favors the non-ionized form of weak acids.
Stomach, because pH < pKa favors the ionized form of weak acids.
Small intestine, because the higher pH increases drug solubility.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Absorption And Bioavailability

Practice Absorption And Bioavailability in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Absorption And Bioavailability, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

A weakly acidic drug with a pKa of 4.0 is administered orally. Considering only the chemical environment, in which location will the drug exist predominantly in its non-ionized, lipophilic form that favors passive membrane diffusion: stomach (pH 2.0) or upper small intestine (pH 6.0)?

  1. Stomach, because pH < pKa favors the non-ionized form of weak acids. (correct answer)
  2. Small intestine, because pH > pKa favors the non-ionized form of weak acids.
  3. Stomach, because pH < pKa favors the ionized form of weak acids.
  4. Small intestine, because the higher pH increases drug solubility.
Explanation: For a weak acid (HA ⇌ H+ + A-), the Henderson-Hasselbalch equation determines the ionization state. When pH < pKa, the equilibrium favors the non-ionized form (HA). In the stomach (pH 2.0), which is less than the pKa (4.0), the drug exists predominantly as HA, the lipophilic form that can cross membranes. In the small intestine (pH 6.0 > pKa 4.0), the drug is predominantly ionized (A-), which is hydrophilic and poorly absorbed by passive diffusion.

Question 2

Drug A and Drug B are both administered orally at the same molar dose. They have identical oral bioavailability (F = 0.8) and elimination half-lives. However, Drug A is formulated as an immediate-release tablet, while Drug B is in a controlled-release formulation. Which of the following statements correctly compares their plasma concentration-time profiles?

  1. Drug B will have a higher Area Under the Curve (AUC) than Drug A.
  2. Drug A will reach its maximum plasma concentration (Cmax) sooner than Drug B. (correct answer)
  3. The total amount of drug absorbed into the systemic circulation will be greater for Drug A.
  4. Drug B will have a higher Cmax than Drug A.
Explanation: Since both drugs have the same oral bioavailability (F), the extent of absorption and the total amount of drug reaching the systemic circulation are the same. Therefore, their Area Under the Curve (AUC) values will be equal. The difference lies in the rate of absorption. The immediate-release formulation (Drug A) will be absorbed more rapidly than the controlled-release formulation (Drug B). This faster absorption rate will lead to Drug A reaching its Cmax at an earlier time point (a shorter Tmax).

Question 3

A patient stabilized on a 400 mg intravenous infusion of an antibiotic every 8 hours is being switched to an oral formulation of the same drug to complete their therapy at home. The oral bioavailability (F) is 75%. To maintain the same total systemic exposure, what should the new oral dose be, administered every 8 hours?

  1. 300 mg
  2. 400 mg
  3. 533 mg (correct answer)
  4. 750 mg
Explanation: To maintain the same systemic exposure, the amount of drug that reaches the systemic circulation must be equivalent for both routes. For an IV dose, bioavailability is 100%. For an oral dose, the amount reaching circulation is Dose_oral × F. The equation is: Dose_IV × F_IV = Dose_oral × F_oral. Since F_IV = 1, we have Dose_IV = Dose_oral × F_oral. We need to find Dose_oral. Rearranging the formula: Dose_oral = Dose_IV / F_oral. Plugging in the values: Dose_oral = 400 mg / 0.75 = 533.33 mg. The closest answer is 533 mg.

Question 4

The oral bioavailability of Drug X is found to decrease as the dose is increased from 10 mg to 100 mg. Which of the following is the most likely mechanism to explain this observation of dose-dependent bioavailability?

  1. The drug's absorption occurs primarily through passive diffusion, which follows first-order kinetics.
  2. The drug undergoes extensive and saturable first-pass metabolism in the liver.
  3. The drug is absorbed via a carrier-mediated transport system that becomes saturated at higher doses. (correct answer)
  4. The drug has very low aqueous solubility that limits its dissolution rate at higher doses.
Explanation: A decrease in bioavailability with an increasing dose suggests a saturable process is involved in absorption. Carrier-mediated active transport is a capacity-limited process. At low doses, the transporters can handle the drug load, but as the dose increases, the transporters become saturated. Once saturated, further increases in drug concentration in the gut lumen do not lead to a proportional increase in the amount of drug absorbed, thus the fraction absorbed (bioavailability) decreases.

Question 5

An orally administered prodrug requires hydrolysis by hepatic esterases to be converted into its active form. The active form is then eliminated by the kidneys. The prodrug itself has poor oral bioavailability due to its chemical properties. How would severe liver disease likely affect the therapeutic efficacy of this drug?

  1. Decrease efficacy due to impaired bioactivation of the prodrug to its active form. (correct answer)
  2. Increase efficacy due to decreased first-pass metabolism of the active drug.
  3. Increase efficacy because higher levels of the parent prodrug will reach systemic circulation.
  4. Have no effect on efficacy since the active drug is eliminated by the kidneys.
Explanation: When you encounter prodrug questions, focus on the conversion pathway and what happens when that pathway is disrupted. Prodrugs are inactive compounds that must be metabolized into their active forms to produce therapeutic effects. In this scenario, the prodrug requires hepatic esterases for bioactivation. Severe liver disease would significantly impair these enzymes, meaning less prodrug gets converted to the active form. Since the prodrug itself is poorly bioavailable and therapeutically inactive, you need that hepatic conversion to occur for any therapeutic benefit. Without adequate liver function, the patient receives minimal active drug despite taking the medication. Let's examine why the other options miss the mark. Option B incorrectly assumes the active drug undergoes first-pass metabolism, but the question states the active form is eliminated by the kidneys, not metabolized by the liver. Option C makes the error of thinking higher prodrug levels would be beneficial - but remember, the prodrug is inactive, so more inactive compound doesn't help therapeutically. Option D overlooks the critical fact that while the active drug is eliminated renally, it must first be created hepatically from the prodrug. The correct answer is A because impaired hepatic esterases directly reduce the conversion of prodrug to active drug, decreasing therapeutic efficacy. Study tip: For prodrug questions, always trace the pathway from administration to elimination. Identify where the rate-limiting step occurs - often the bioactivation step - and consider how disease states affect that specific process. The elimination route of the active drug matters less than the generation of that active drug.

Question 6

A patient with decreased GI motility due to diabetic gastroparesis is given an oral enteric-coated tablet. This formulation is designed to release the drug only when the pH is above 6.0. How will this patient's condition most likely affect the drug's absorption profile?

  1. A significant delay in the onset of action and potentially reduced overall absorption. (correct answer)
  2. A significant increase in the rate and extent of absorption due to longer contact time.
  3. Rapid absorption and a higher Cmax because the tablet will dissolve in the stomach.
  4. No change in the absorption profile, as enteric coatings are independent of GI motility.
Explanation: When you encounter questions about drug formulations and GI conditions, think about how the formulation's design interacts with normal physiological processes and what happens when those processes are disrupted. Enteric-coated tablets are specifically designed to resist dissolution in the acidic stomach (pH ~1-3) and only release their contents in the more alkaline small intestine (pH >6.0). This requires the tablet to transit from stomach to duodenum, where the higher pH triggers coating dissolution. In diabetic gastroparesis, decreased GI motility means significantly delayed gastric emptying - the tablet sits in the acidic stomach much longer than normal before reaching the alkaline environment needed for drug release. This delayed transit leads to Answer A being correct: you'll see a significant delay in onset of action (since drug release is postponed) and potentially reduced overall absorption. The prolonged gastric residence time may also compromise the enteric coating's integrity or lead to some drug degradation. Answer B is wrong because longer contact time doesn't help if the drug isn't being released - the coating remains intact in the acidic stomach. Answer C misunderstands enteric coatings entirely; these tablets are designed NOT to dissolve in stomach acid, so gastroparesis won't cause premature dissolution. Answer D ignores the fundamental requirement that enteric-coated formulations depend on normal gastric emptying to reach their target release site. Study tip: Remember that modified-release formulations rely on normal GI physiology. When you see questions pairing special formulations with GI motility disorders, always consider how the condition disrupts the formulation's intended release mechanism.

Question 7

A new drug that is a substrate for an intestinal uptake transporter shows linear, dose-proportional pharmacokinetics at therapeutic doses. If this drug is co-administered with a potent inhibitor of that specific uptake transporter, what is the most likely outcome?

  1. An increase in the drug's Tmax and Cmax.
  2. A decrease in the drug's volume of distribution (Vd).
  3. An increase in the drug's hepatic extraction ratio.
  4. A decrease in the drug's oral bioavailability (F). (correct answer)
Explanation: When you encounter questions about drug transporters and pharmacokinetics, focus on how transporters affect drug movement across biological membranes and the resulting impact on drug exposure. Intestinal uptake transporters facilitate drug absorption from the gut into systemic circulation. When a potent inhibitor blocks this transporter, the drug can no longer efficiently cross the intestinal membrane. This creates a bottleneck at the absorption step, meaning less drug reaches the bloodstream compared to when the transporter functions normally. Since oral bioavailability (F) represents the fraction of an orally administered dose that reaches systemic circulation unchanged, blocking the uptake mechanism directly reduces F. Let's examine why the other options don't fit: (A) is incorrect because inhibiting uptake would decrease, not increase, both Tmax and Cmax since less drug is absorbed and absorption becomes slower. (B) misses the mark because volume of distribution reflects how extensively a drug distributes into tissues once it's in the bloodstream—transporter inhibition affects getting into the blood, not distribution afterward. (C) is wrong because hepatic extraction ratio depends on liver metabolism and blood flow, not intestinal absorption transporters. The key pattern to remember: transporter inhibition always opposes the transporter's normal function. If an uptake transporter normally helps absorption, its inhibition will reduce absorption and bioavailability. This is a common mechanism for drug-drug interactions, especially with medications that depend heavily on specific transporters for absorption.

Question 8

A patient with celiac disease, which causes villous atrophy and a significant reduction in the surface area of the small intestine, is taking an oral medication that is absorbed primarily by passive diffusion. How would this patient's condition be expected to affect the pharmacokinetics of the drug?

  1. First-pass metabolism will be significantly increased.
  2. The pharmacokinetics will be unaffected as passive diffusion is not carrier-mediated.
  3. The drug will be absorbed more rapidly due to increased gut permeability.
  4. The rate and extent of absorption will likely be reduced. (correct answer)
Explanation: When analyzing drug absorption changes due to gastrointestinal pathology, you need to consider how the anatomical and physiological alterations affect the absorption process, regardless of the mechanism involved. Celiac disease causes villous atrophy, which dramatically reduces the surface area available for absorption in the small intestine. Even though this drug is absorbed by passive diffusion (a non-carrier-mediated process), absorption still depends on having adequate surface area for the drug molecules to cross from the intestinal lumen into the bloodstream. With significantly reduced surface area, both the rate (how quickly) and extent (how much total drug) of absorption will decrease, making D correct. Let's examine why the other options are incorrect: A suggests increased first-pass metabolism, but celiac disease primarily affects absorption in the small intestine, not hepatic metabolism. The liver's metabolic capacity remains unchanged. B contains a dangerous misconception—while passive diffusion isn't carrier-mediated, it absolutely still requires surface area. Reducing surface area will impair any absorption mechanism. C proposes increased absorption due to enhanced permeability, but this misunderstands the pathophysiology. Although intestinal inflammation can increase permeability in some conditions, the massive loss of surface area from villous atrophy far outweighs any permeability changes. Remember this key principle: drug absorption depends on both the mechanism (passive diffusion, active transport, etc.) and the available surface area. When you encounter questions about GI diseases affecting drug absorption, always consider how the anatomical changes impact the total absorptive surface, regardless of the specific transport mechanism involved.

Question 9

A drug is available in two oral dosage forms: a 250 mg immediate-release tablet and a 500 mg extended-release tablet. Both are designed to be taken once daily and are bioequivalent, meaning they deliver the same total amount of drug to the systemic circulation over 24 hours. Which statement accurately reflects the relationship between their AUC values?

  1. The AUC of the 500 mg tablet will be double the AUC of the 250 mg tablet.
  2. Bioequivalence cannot be claimed if the doses and AUCs are not identical.
  3. The AUC of the 250 mg tablet will be higher due to its faster absorption.
  4. The AUC values for the two formulations will be approximately equal. (correct answer)
Explanation: When evaluating bioequivalent formulations, focus on understanding what bioequivalence actually means and how AUC (area under the curve) relates to total drug exposure. The correct answer is D because bioequivalence is defined by comparable AUC values, not identical doses. Since both formulations are stated to be bioequivalent and deliver the same total amount of drug to systemic circulation over 24 hours, their AUC values must be approximately equal. The AUC represents total drug exposure over time, and if two formulations provide equivalent bioavailability, their AUCs will match regardless of the individual tablet strengths or release patterns. Option A incorrectly assumes that AUC scales directly with tablet strength. However, since you take different numbers of tablets (likely two 250 mg vs. one 500 mg), the total daily doses are equivalent, making their AUCs comparable, not different by a factor of two. Option B misunderstands bioequivalence criteria. Bioequivalence is established through AUC and Cmax comparisons, not by having identical doses. Different formulations can achieve bioequivalence through various dose strengths and release mechanisms. Option C incorrectly suggests that faster absorption increases total exposure (AUC). While immediate-release formulations absorb faster, this affects the rate of absorption (reflected in Cmax and Tmax), not the extent of absorption (AUC). Faster absorption creates a higher, narrower peak but doesn't increase total drug exposure. Remember: AUC reflects total drug exposure over time. When formulations are truly bioequivalent, their AUCs will be comparable regardless of release kinetics or individual tablet strength.

Question 10

A patient with severe hepatic cirrhosis is to be treated with a drug that has a high hepatic extraction ratio (E > 0.7) and is administered orally. Which pharmacokinetic parameter is most likely to be significantly increased in this patient compared to a person with normal liver function?

  1. Rate of absorption (ka)
  2. Fraction of drug excreted unchanged in urine (fe)
  3. Oral bioavailability (F) (correct answer)
  4. Volume of distribution (Vd)
Explanation: A high hepatic extraction ratio means the drug undergoes extensive first-pass metabolism in the liver. In a patient with severe hepatic cirrhosis, the liver's metabolic capacity is significantly reduced. When the drug is administered orally, it passes through the liver before reaching systemic circulation. The impaired liver function leads to a reduction in first-pass metabolism, allowing a much larger fraction of the absorbed dose to reach the systemic circulation. This results in a significant increase in oral bioavailability (F).

Question 11

A clinical study is conducted to compare a new generic formulation of a drug to the established brand-name product. The 90% confidence intervals for the ratio of the generic to brand product for key pharmacokinetic parameters were as follows:

  • AUC: (0.95, 1.10)
  • Cmax: (0.85, 1.28)

Based on standard regulatory criteria for bioequivalence and the study results presented in the passage, which conclusion can be drawn?

  1. The generic product is bioequivalent because the confidence interval for AUC is within the acceptable range.
  2. The generic product is not bioequivalent because the confidence interval for Cmax extends beyond the acceptable range. (correct answer)
  3. The products are bioequivalent because the point estimates for the ratios are likely close to 1.0.
  4. The bioequivalence of the products cannot be determined without knowing the Tmax values.
Explanation: For two products to be considered bioequivalent, the 90% confidence intervals for the ratio of the geometric means (generic/brand) for both AUC (Area Under the Curve) and Cmax (peak concentration) must fall entirely within the range of 0.80 to 1.25. In this case, the 90% CI for AUC is (0.95, 1.10), which is within the acceptable range. However, the 90% CI for Cmax is (0.85, 1.28). Since the upper limit of 1.28 exceeds the 1.25 boundary, the generic product fails to meet the bioequivalence criteria for Cmax.

Question 12

Rectal administration of a drug can result in partially bypassing first-pass metabolism. This is because the venous drainage from the rectum is bifurcated. Which of the following statements most accurately describes this anatomical arrangement?

  1. The entire rectal venous plexus drains into the portal vein, but the slow absorption limits hepatic metabolism.
  2. The rectum contains unique metabolic enzymes that degrade drugs locally, reducing the amount that reaches the liver.
  3. The inferior rectal vein drains to the portal system, while the superior and middle veins drain to the systemic circulation.
  4. The superior rectal veins drain to the portal system, while the middle and inferior rectal veins drain to the systemic circulation. (correct answer)
Explanation: When you encounter questions about rectal drug administration and first-pass metabolism, focus on the unique venous drainage pattern that makes this route clinically valuable. The rectum's bifurcated venous drainage allows some drug absorption to bypass the liver entirely, which is why rectal medications can be more bioavailable than oral ones. The key anatomical arrangement involves three sets of rectal veins with different destinations. The superior rectal veins drain into the inferior mesenteric vein, which flows to the portal circulation and through the liver before reaching systemic circulation. However, the middle and inferior rectal veins drain directly into the internal iliac veins, bypassing the liver and entering systemic circulation immediately. This creates the "partial bypass" effect that makes rectal administration advantageous for certain medications. Choice A incorrectly states that the entire rectal plexus drains to the portal system - this would eliminate any first-pass bypass advantage. Choice B focuses on local enzymatic degradation rather than the vascular anatomy that actually explains the bypass effect. Choice C reverses the drainage pattern, incorrectly placing the inferior rectal vein in the portal system when it actually drains systemically. Choice D correctly identifies that superior rectal veins drain to the portal system while middle and inferior rectal veins drain systemically, explaining the partial first-pass bypass. Remember this pattern: "Superior goes to portal, middle and inferior go systemic." This anatomical principle explains why rectal drug administration can achieve higher bioavailability than oral routes for hepatically metabolized drugs.

Question 13

The volume of distribution (Vd) of a drug is 10 L and its clearance (CL) is 20 L/hr. Its oral bioavailability (F) is 50%. If the therapeutic plasma concentration is 2 mg/L, what is the appropriate oral loading dose to rapidly achieve this concentration?

  1. 10 mg
  2. 20 mg
  3. 40 mg (correct answer)
  4. 100 mg
Explanation: This question requires a multi-step calculation combining concepts of loading dose and bioavailability. The standard formula for a loading dose (LD) is LD = Vd × C_target, where C_target is the target plasma concentration. This formula calculates the IV loading dose. For an oral loading dose, this amount must be corrected for bioavailability: LD_oral = (Vd × C_target) / F. The clearance value is extraneous information designed to distract the test-taker. Calculation: LD_oral = (10 L × 2 mg/L) / 0.50 = 20 mg / 0.50 = 40 mg.

Question 14

A drug that undergoes extensive enterohepatic circulation is administered to a patient who is subsequently started on cholestyramine, a bile acid sequestrant. What is the most likely consequence of this drug interaction?

  1. An increase in the drug's oral bioavailability due to enhanced reabsorption.
  2. A decrease in the drug's elimination half-life due to interruption of recycling. (correct answer)
  3. A delay in the time to reach peak plasma concentration (Tmax) with no change in AUC.
  4. A selective reduction in first-pass metabolism, leading to higher peak concentrations.
Explanation: Enterohepatic circulation involves the excretion of a drug or its metabolite into the bile, followed by reabsorption from the small intestine. This recycling process effectively prolongs the drug's presence in the body, increasing its elimination half-life. Cholestyramine is a resin that binds bile acids (and many drugs) in the intestine, preventing their reabsorption. By binding the excreted drug or its metabolite in the gut, cholestyramine interrupts the enterohepatic recycling loop. This interruption increases the net clearance of the drug, leading to a shorter elimination half-life and a lower overall drug exposure (AUC).

Question 15

A new drug is being evaluated. After a 50 mg intravenous dose, the AUC is 800 ng·hr/mL. After a 200 mg oral dose, the AUC is 1600 ng·hr/mL. What is the absolute oral bioavailability (F) of this drug?

  1. 25%
  2. 50% (correct answer)
  3. 100%
  4. 200%
Explanation: Absolute bioavailability (F) is calculated using the formula: F = (AUC_oral / AUC_IV) × (Dose_IV / Dose_oral). This formula normalizes the AUC for the dose administered. Plugging in the values from the question: F = (1600 ng·hr/mL / 800 ng·hr/mL) × (50 mg / 200 mg). This simplifies to: F = 2 × (1/4) = 0.50. Expressed as a percentage, the bioavailability is 50%.

Question 16

Which of the following sets of physicochemical properties is most characteristic of a drug that is well-absorbed from a transdermal patch?

  1. Low molecular weight, moderate lipophilicity, and a high therapeutic potency. (correct answer)
  2. High molecular weight, high water solubility, and ionized at skin pH.
  3. Low water solubility, high melting point, and subject to extensive first-pass metabolism.
  4. High lipophilicity, a daily dose requirement greater than 20 mg, and rapid metabolism.
Explanation: When evaluating transdermal drug delivery, you need to consider how drugs must penetrate the skin's barrier—the stratum corneum—to reach systemic circulation. This lipid-rich layer favors specific molecular characteristics for successful drug permeation. Option A correctly identifies the ideal transdermal properties. Low molecular weight (typically <500 Da) allows drugs to navigate between skin cells more easily. Moderate lipophilicity provides the right balance—enough to dissolve through lipid barriers but not so much that the drug gets trapped in fatty tissue. High therapeutic potency is crucial because transdermal patches deliver relatively small amounts of drug compared to oral routes, so you need a drug that's effective at low doses. Option B fails because high molecular weight drugs struggle to penetrate skin, while high water solubility and ionization at skin pH (around 5.5) prevent effective passage through the lipophilic stratum corneum. Option C is problematic since low water solubility combined with high melting point suggests poor drug release from the patch matrix, making absorption inefficient. While avoiding first-pass metabolism is actually an advantage of transdermal delivery, the other properties negate this benefit. Option D's high daily dose requirement (>20 mg) is impractical for patches due to size limitations, and rapid metabolism would necessitate frequent patch changes. Remember this key principle: transdermal drugs need to be "just right"—small enough to penetrate, lipophilic enough to cross barriers, but potent enough to work at the low doses that patches can practically deliver.

Question 17

Which of the following describes the primary advantage of sublingual administration for a drug like nitroglycerin, which is susceptible to a high first-pass effect?

  1. The sublingual route provides a larger surface area for absorption than the small intestine.
  2. The pH of the oral mucosa is neutral, which enhances the absorption of most drugs.
  3. The drug is absorbed into the systemic venous circulation, bypassing the portal circulation. (correct answer)
  4. The drug dissolves slowly, providing a sustained therapeutic effect over many hours.
Explanation: The primary advantage of the sublingual route is that it bypasses first-pass metabolism in the liver. The rich vasculature under the tongue drains directly into the superior vena cava via the jugular vein. This allows the drug to enter the systemic circulation directly, avoiding the portal vein and subsequent passage through the liver before distribution to the rest of the body. This is crucial for drugs like nitroglycerin that are extensively metabolized by the liver.

Question 18

A highly lipophilic drug is administered orally. How would co-administration with a high-fat meal most likely affect the drug's absorption and bioavailability (F)?

  1. Decrease F by delaying gastric emptying and exposing the drug to acidic degradation.
  2. Increase F by stimulating bile secretion, which emulsifies fats and solubilizes the drug. (correct answer)
  3. Decrease F because the drug will partition into the fat in the meal and not be available for absorption.
  4. Have no effect on F, as absorption of lipophilic drugs is independent of GI contents.
Explanation: For highly lipophilic (fat-soluble) drugs, a major barrier to absorption is their poor dissolution in the aqueous environment of the GI tract. A high-fat meal stimulates the release of bile from the gallbladder. Bile salts are amphipathic molecules that act as detergents, emulsifying fats and forming micelles. The lipophilic drug can partition into these micelles, which significantly increases its solubilization and subsequent absorption across the intestinal wall. This leads to an increase in both the rate and extent of absorption (increased F).